UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000041452
Receipt number R000046899
Scientific Title Estimation of cost value based on the convenience of an anti-influenza agent baloxavir marboxil
Date of disclosure of the study information 2020/08/18
Last modified on 2022/02/22 16:16:39

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Estimation of cost value based on the convenience of an anti-influenza agent baloxavir marboxil

Acronym

Estimation of cost value based on the convenience of an anti-influenza agent baloxavir marboxil

Scientific Title

Estimation of cost value based on the convenience of an anti-influenza agent baloxavir marboxil

Scientific Title:Acronym

Estimation of cost value based on the convenience of an anti-influenza agent baloxavir marboxil

Region

Japan


Condition

Condition

influenza

Classification by specialty

Infectious disease

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To estimate the monetary value of convenience of an influenza drug baloxavir marboxil, which is taken orally and one time, for patients, particularly considering the route and frequency of administration.

Basic objectives2

Others

Basic objectives -Others

convenience

Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Convenience of drugs: route, frequency, and duration of administration, and out-of-pocket expenses

Key secondary outcomes



Base

Study type

Others,meta-analysis etc


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

64 years-old >=

Gender

Male and Female

Key inclusion criteria

Individuals who were prescribed any influenza drugs (oral or inhalation) last season (from October 2018 to April 2019) or this season (from October 2019 to the present)

Key exclusion criteria

N/A

Target sample size

3000


Research contact person

Name of lead principal investigator

1st name Shinzo
Middle name
Last name Hiroi

Organization

Shionogi & CO., LTD.

Division name

Medical Affairs Dept.

Zip code

530-0012

Address

1-1-4, Shibata, Kita-ku Osaka

TEL

06-6485-5201

Email

shinzo.hiroi@shionogi.co.jp


Public contact

Name of contact person

1st name Akira
Middle name
Last name Yokomasu

Organization

Shionogi & CO., LTD.

Division name

Medical Affairs Dept.

Zip code

530-0012

Address

1-1-4, Shibata, Kita-ku Osaka

TEL

06-6485-5201

Homepage URL


Email

akira.yokomasu@shionogi.co.jp


Sponsor or person

Institute

Shionogi & CO., LTD.

Institute

Department

Personal name



Funding Source

Organization

Shionogi & CO., LTD.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

RIHDS Ethical Review Board

Address

12th Floor, Suitomo Shiba Daimon Building, 2-5-5 Shiba Daimon, Minato-ku, Tokyo, Japan

Tel

03-5733-5010

Email

rihds@jmdc.co.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2020 Year 08 Month 18 Day


Related information

URL releasing protocol

N/A

Publication of results

Published


Result

URL related to results and publications

https://www.tandfonline.com/doi/full/10.1080/13696998.2021.1877150

Number of participants that the trial has enrolled

3137

Results

The monetary value for oral antivirals was estimated to be higher, saving JPY 741 (USD 7.06, as of August 2020), compared with inhalant. Regarding the length and frequency of administration, five days corresponds to an increase of JPY 2,072, compared with one day, and twice a day corresponds to a JPY 574 increase compared to once a day.

Results date posted

2022 Year 02 Month 22 Day

Results Delayed


Results Delay Reason


Date of the first journal publication of results

2021 Year 02 Month 12 Day

Baseline Characteristics

Individuals who were prescribed any influenz
a drugs (oral or inhalation) last season (fr
om October 2018 to April 2019) or this seaso
n (from October 2019 to the present)

Participant flow

We used an online panel managed by research company for the online survey. The respondents were selected by screening questions.

Adverse events

N/A

Outcome measures

Convenience of drugs: route, frequency, and
duration of administration). The values were converted as montetary values based on the utility of out-of-pocket expenses.

Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2020 Year 07 Month 20 Day

Date of IRB

2020 Year 08 Month 18 Day

Anticipated trial start date

2020 Year 08 Month 18 Day

Last follow-up date

2020 Year 08 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

A questionnaire survey will be performed for the eligible individuals in research panel in a research company.
The results of survey will be analyzed by conjoint analysis.


Management information

Registered date

2020 Year 08 Month 18 Day

Last modified on

2022 Year 02 Month 22 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000046899


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name